Mayzent (siponimod)
- Region
- 🇪🇺 EU
- Active substance
- siponimod
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Multiple Sclerosis, Relapsing-Remitting
- CHMP opinion
- Thu 14 Nov 2019
- EU approval
- Mon 13 Jan 2020
- Application
- EMEA/H/C/004712
- ATC
- L04
- Official record
- www.ema.europa.eu
Indication
Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
Regulatory milestones
No milestones recorded in the last year.
Follow Mayzent
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.